Table 1 Baseline data of the studied patients

Age/year

49 ± 7.7

49.4 ± 6.5

NS

 Male: N(%)

42(41.18%)

27(54%)

NS

 Female:N(%)

60(58.82%)

23(46%)

Body mass index (BMI)

24.5 ± 5.01

23.4 ± 5.2

NS

Duration of disease(years)

17.02 ± 7.6

 FEV₁%

42.04 ± 6.8

83.64 ± 4.4

< 0.001*

 Pre-FEV₁(L)

1.40 ± 0.5

2.56 ± 0.5

 Post-FEV₁(L)

1.93 ± 0.7

 FVC%

72.55 ± 7.2

94.46 ± 8.5

 Bronchodilator reversibility (ml):

465.51 ± 35.2

Frequency of hospital admission last year:(n/%)

Non: 40(39.2%)

Once: 60(58.8%)

Twice: 2 (2%)

 Symptom score:

62.89 ± 9.3

6.19 ± 0.6

< 0.001*

 Impact score:

58.23 ± 15.1

9.83 ± 0.4

 Activity score:

59.71 ± 12.6

6.49 ± 0.3

 Total score:

12.6 ± 59.45

0.2 ± 8.17

 HADS-D:

8.24 ± 2.4

5.89 ± 0.3

< 0.001*

 BDI:

16.35 ± 6.3

8.84 ± 0.7

 HADS-A:

8.24 ± 1.8

6.38 ± 0.4

< 0.001*

 HAMA:

13.20 ± 2.6

10.20 ± 1.1